From a missing sign turning up across the Irish sea, to cancelled festivals and teenagers locked in a play park - here are ...

Hayden Yung finds ways to persevere with muscular dystrophy, but experts say targeted help is needed both for children and ...

FIRDAPSE boosts Catalyst's strong Q1 2025 results, beating forecasts. With 15–20% growth projected, see why analysts rate ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Contributed by Louis M. Kunkel, April 18, 2017 (sent for review March 6, 2017; reviewed by Jeffrey S. Chamberlain and Melissa J. Spencer) ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

After taking a day for reflection on her sons' lives with DMD, columnist Betty Vertin says she feels more on top of their care.

BofA lowered the firm’s price target on PepGen (PEPG) to $1 from $3 and keeps an Underperform rating on the shares after the company announced it will be discontinuing development of Duchenne muscular ...

Timing of the surgery varies and may be dictated by the underlying disorder. In the presence of muscular dystrophy, for example, we consider surgical intervention once the child is wheelchair-bound, ...

Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduce ...

PepGen to focus on development of DM1 programme following 10 mg/kg PGN-EDO51 update: Boston Friday, May 30, 2025, 14:00 Hrs [IST] PepGen Inc, a clinical-stage biotechnology compan ...